Screener
Travere Therapeutics, Inc. TVTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | Three Months Ended March 31, 2026 / Shares | Three Months Ended March 31, 2026 / Net Loss | Three Months Ended March 31, 2026 / EPS | Three Months Ended March 31, 2025 / Shares | Three Months Ended March 31, 2025 / Net Loss | Three Months Ended March 31, 2025 / EPS |
|---|---|---|---|---|---|---|
| Continuing operations | 91,868,862 | $(36,602) | $(0.40) | 88,355,973 | $(41,226) | $(0.47) |
| Discontinued operations | 91,868,862 | (500) | — | 88,355,973 | — | — |
| Basic and diluted loss per share | 91,868,862 | $(37,102) | $(0.40) | 88,355,973 | $(41,226) | $(0.47) |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s EPS (diluted)?
- Travere Therapeutics, Inc. (TVTX) reported EPS (diluted) of -$0.40 in Q1 2026.
- How has Travere Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Travere Therapeutics, Inc.'s EPS (diluted) increased by 14.9% year-over-year, from -$0.47 to -$0.40.
- What is the long-term trend for Travere Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s EPS (diluted) has grown at a 10.4% compound annual growth rate (CAGR), from -$3.03 to -$4.08.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Travere Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude